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In climacteric and postmenopausal women,
low serum levels of 17β-estradiol (E2) often
result in symptoms such as hot flashes or
degenerative processes such as osteoporosis.
This has prompted women to receive hor-
mone replacement therapy (HRT) to prevent
these ageing-associated symptoms or diseases
(Burger 2003). Because estrogens alone stim-
ulate endometrial proliferation, which may
result in cancer, they have to be given in
combination with progestins (Albertazzi and
Sharma 2005). This has resulted in massive
consumption of estrogens in combination
with progestins. The recent Women’s Health
Initiative and the British Million Women
Study have thrown doubts on the exclusively
beneﬁcial effect of HRT, particularly because
a higher incidence of mammary cancers and
arteriosclerotic complications such as heart
attacks and strokes were reported (Beral
2003; Rossouw et al. 2002). This has
resulted in a search for HRT alternatives and
plant-derived, so-called phytoestrogens are
vigorously promoted.
Genistein (GEN) is an isoflavone found
mainly in soy (Glycine max) and red clover
(Trifolium pratense), and its estrogenic activity
has been reported (Boue et al. 2003; Cos
et al. 2003). The estrogenicity of GEN can be
explained by the molecular similarity between
GEN and E2 and their transactivational prop-
erties via estrogen receptors (ERs) (Bovee
et al. 2004; Mueller et al. 2004; Ricketts et al.
2005; Sirtori et al. 2005).
A second ER (ER-β) was cloned in 1996
from rat prostate tissue (Kuiper et al. 1996).
This ER-β was also found to be expressed in
humans (Mosselman et al. 1996). Its distribu-
tion pattern is different from the former
known ER, now called ER-α (Pelletier et al.
2000; Saunders et al. 1997; Shughrue et al.
1998).
Companies that produce products con-
taining soy or red clover as food additives
claim exclusive beneficial effects in post-
menopausal women; hence, they advertise
their products as selective ER modulators.
E2 binds to both receptors with appar-
ently no difference in affinity, and recent
binding assays showed that GEN had a
higher affinity to ER-β than to ER-α
(Kuiper et al. 1998). In reporter cell systems,
however, GEN transactivated both ERs with
similar potency (Mueller et al. 2004). In
short-term animal studies, GEN stimulated
uterine growth (Diel et al. 2004; Kanno et al.
2003). In the uterus, E2 stimulates endome-
trial proliferation; this stimulation, without
addition of progestins, will result in endome-
trial hyperplasia and eventually neoplasia
(Albertazzi and Sharma 2005). In a placebo-
controlled 5-year-long clinical study, Unfer
et al. (2004) found that a soy product con-
taining 150 mg isoflavones stimulated the
endometrium of women such that 3.37%
developed endometrial hyperplasia, which
was not observed in any of the placebo-
treated women.
Another target for E2 is the vagina, where
proliferation and corniﬁcation of the epithe-
lium are induced; these are desired estrogenic
effects because the lactobacillae use these cells
to produce lactic acid, which keeps the vaginal
milieu acidic and thus prevents ascending
infections (Heinemann and Reid 2005).
Another undesired effect of E2 is stimula-
tion of proliferation of mammary gland tissue.
Proliferation-promoting and -inhibiting
effects of GEN on human mammary cancer
cells and on mammary cancers in a variety of
animal models have been described and
remain controversial (Allred et al. 2004; Dave
et al. 2005; Harris et al. 2005; Jeune et al.
2005; Kijkuokool et al. 2005; Kousidou et al.
2005; Liu et al. 2005; Schmidt et al. 2005;
Vantyghem et al. 2005). Early exposure of
pubertal rats or girls to soy or genistein has
been shown to have a preventive effect on
mammary cancer development during adult-
hood (Cabanes et al. 2004; Lamartiniere
2002). Negligible effects on climacteric com-
plaints and bones have also been reported
(Geller and Studee 2005; Krebs et al. 2004;
Phipps et al. 2002) under the treatment with
soy or red clover products. Hence, it is an open
question whether GEN has exclusively beneﬁ-
cial effects, as claimed by industrial companies,
or whether they are endocrine disruptors that
endanger the mammary gland or the uterus.
Furthermore, little is known about the biologi-
cal effects of GEN after long-term oral
administration, which is the common method
of treatment in postmenopausal women.
The ovariectomized (ovx) rat is a widely
used model to study estrogen withdrawal and
replacement because many phenomena in this
rat model are similar to those occurring in
postmenopausal women. Therefore, we ana-
lyzed a number of physiologic and morpho-
logic effects induced in the mammary gland,
uterus, and vagina after long-term (3 months)
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BACKGROUND: The isoflavone genistein (GEN) is found in soy (Glycine max) and red clover
(Trifolium pratense). The estrogenic activity of GEN is known, and it is widely advertised as a phyto-
estrogen useful in alleviating climacteric complaints and other postmenopausal disorders. Knowledge
of effects of long-term administration of GEN in laboratory animals is scarce, and effects in the
uterus and mammary gland after long-term administration have not been studied. The uterus and
mammary gland are known to be negatively inﬂuenced by estrogens used in hormone therapy.
OBJECTIVES: We administered two doses of GEN [mean daily uptake 5.4 (low) or 54 mg/kg (high)
body weight (bw)] orally over a period of 3 months to ovariectomized (ovx) rats and compared the
effects with a treatment with two doses of 17β-estradiol [E2; 0.17 (low) or 0.7 mg/kg bw (high)].
Mammary glands, vaginae, and uteri were investigated morphologically and immuno-
histochemically. We quantified the expression of proliferating cell nuclear antigen (PCNA) and
progesterone receptor (PR) in the mammary gland.
RESULTS: In rats treated with either of the E2 doses or the high GEN dose, we found increased uter-
ine weight, and histologic analysis showed estrogen-induced features in the uteri. In vaginae, either
E2 dose or GEN high induced hyperplastic epithelium compared with the atrophic controls. In the
mammary gland, E2 (either dose) or GEN increased proliferation and PR expression. Serum levels
of luteinizing hormone were decreased by E2 (both doses) but not by GEN.
CONCLUSIONS: In summary, E2 and GEN share many effects in the studied organs, particularly in
the vagina, uterus, and mammary gland but not in the hypothalamo/pituitary unit.
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2007]oral administration of two doses of GEN in
ovx rats and compared them with those
induced by E2 treatment. In the present study,
tissue samples were analyzed histologically and
immunocytochemically. E2-induced effects on
body weight and in uterus and vagina are well
known (Albertazzi and Sharma 2005; Asarian
and Geary 2006; Heinemann and Reid 2005)
and allow comparison with effects of test sub-
stances. E2-induced effects in the mammary
gland have not been well described and there-
fore we defined own parameters; thus, this
study provides not only information on effects
of long-term oral administration of GEN but
also quantitative data on the effects of E2 in
this tissue. E2 stimulates mammary gland pro-
liferation by a mechanism that involves ER-α
(Tekmal et al. 2005); this has been associated
with the increased risk of cancer development
because DNA damage might occur during
replication (Krebs et al. 2004). Therefore, we
performed proliferation-speciﬁc analyses and
determined expression of the progesterone
receptor (PR), which is stimulated in the
mammary gland after E2 exposure (Tekmal
et al. 2005). Cells expressing both proliferat-
ing cell nuclear antigen (PCNA) protein and
PR protein were quantified after immuno-
histochemical staining.
Materials and Methods
Animals and chemical exposures. Permission
for this study was given by the Bezirksregierung
(Az. 509.42502/01-36.03), which precludes
inhumane treatment and painful experimenta-
tion. Sprague-Dawley rats were fed soy-free
food during and after breeding, and body
weights of each animal were recorded before
and at termination of the experiment. Bilateral
ovx was performed under isoﬂurane anesthesia
at the age of 3 months, and animals were
divided into five groups (n = 11–12/group).
One group was left on soy-free food after ovx.
Food was soy-free pelleted chow supple-
mented with potato proteins (D-59494;
Ssniff Spezialdiäten GmbH, Soest, Germany).
Immediately after ovx, animals in four of the
groups received the same chow with added E2
[0.17 or 0.7 mg/kg body weight (bw)] or
GEN (5.4 or 54 mg/kg bw].
E2 was given as estradiolbenzoate (catalog
no. 8515, purity of 98.5%; Sigma, Munich,
Germany). Genistein (catalog no. SG
20030618, purity of 98.5%) was a commercial
product of Chemos (Regensburg, Germany).
We checked the purity of the isoflavone by
HPLC and ultraviolet (UV) detection at
260 nm. The HPLC conditions were gradient
elution with 70% A (water containing 0.085%
o-phosphoric acid), 30% B (acetonitril) for
0 min; 25% A, 75% B for 15 min; and a
250 × 4 mm C18 reverse-phase column with a
ﬂow rate of 1 mL/min.
Animals were fed these diets for 3 months
and housed under standardized conditions
(lights on 12 hr from 0600 hours to
1800 hours; room temperature, 23°C; 5–6 ani-
mals per cage) with free access to water and
food. We estimated intake of the test sub-
stances from the mean food intake in each cage
divided by the number of animals per cage.
The daily food intake per animal was as fol-
lows: controls, 18.7 g; E2 low, 15.4 g; E2 high,
14.0 g; GEN low, 18.8 g; and GEN high,
15.5 g. On the basis of food intake, we esti-
mated that the daily exposure to free E2 or
GEN per animal (in milligrams per kilograms
body weight) was as follows: E2 low, 0.17;
E2 high, 0.7; GEN low, 5.4; GEN high, 53. 
Tissue samples. Animals were sacriﬁced by
decapitation under CO2 anesthesia between
0900 and 1200 hours; blood was collected
from the trunk, and serum was stored at
–20°C until analysis of E2 by radioimmuno-
assay (3rd Generation RIA Kit; DSL GmbH,
Sinsheim, Germany). Sera of the GEN-treated
animals were extracted using the SEP-PAK
cartridges solid-phase method according to
the standard protocol suggested by the manu-
facturer (Waters, Eschborn, Germany), and
ethanol-redissolved aliquots were subjected to
HPLC separation and UV-detection as
described above. 
The uteri were removed and weighed, and
the fifth mammary glands and vaginae were
collected. All samples were fixed in 10%
buffered formalin for 48 hr. Uteri were cut
such that three cross-sections per area could
be prepared at proximal, medial, and distal
areas. Mammary glands were cut to obtain
sections from the nipple through the fat pad
toward the abdominal muscles. Vaginae were
prepared for longitudinal sections. All samples
were embedded in paraffin, and 3-µm thick
sections were cut, mounted, and stained with
hematoxylin and eosin (H&E) for micro-
scopic analysis.
Immunohistochemical analysis. We per-
formed immunohistochemistry in mammary
gland sections to identify PCNA and PR. After
antigen retrieval using microwave radiation
and citrate buffer (Ezaki 2000), we immunola-
beled tissue sections with a monoclonal anti-
body for PCNA (PC-10, sc 56; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or a
polyclonal antibody for PR (C19, sc 538;
Santa Cruz Biotechnology). The tissue sections
were then immunostained using peroxidase
and diaminobenzidine (EnVision Detection
System, Peroxidase/DAB, rabbit/mouse,
K5007; Dako Cytomation, Hamburg,
Germany). Sections were then stained with
H&E. We quantiﬁed the number of PCNA-
and PR-immunoreactive cells in alveolar and
terminal buds of the mammary gland on one
slide for each of the 11–12 animals per group;
400–600 cells were counted per slide. The
number of PCNA- or PR-expressing cells was
expressed as the percentage of the total number
of mammary gland cells.
Morphologic analyses. For morphologic
analyses of uterus, we recorded known E2-
induced features including shape and polarity
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Table 1. Initial and ﬁnal body weights (grams) of E2- and GEN-treated ovx rats (mean ± SEM).
Treatment
Time point Control E2 low E2 high GEN low GEN high
Initial bw 256 ± 5.5 268 ± 5.8 261 ± 3.1 264 ± 6.6 250 ± 3.8
Final bw 341 ± 8.1* 286 ± 9.8*,**  258 ± 5.2** 354 ± 8.1* 293 ± 4.3*,**
*p < 0.05 compared with initial control weight. **p < 0.5 compared with ﬁnal control weight.
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Figure 1. Serum levels (mean ± SEM) of E2 (A) and LH (B) in ovx rats after 3 months of treatment. Note the
dose-dependent reduction of LH by E2 and the lacking effect of GEN. 
#p > 0.01 compared with control.
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Figure 2. Uterine wet weights (mean ± SEM) of ovx
rats after 3 months of treatment with E2 or GEN.
Note the stimulating effects of both E2 doses and
the GEN high. The dashed line indicates the aver-
age uterine wet weight for an intact female rat.
#p < 0.01 compared with control.of the lamina propia cells, epithelial mitotic
ﬁgures and necrosis, determination of hyper-
trophy and hyperplasia of glands and
endometrial epithelium, and pathologic fea-
tures such as squamous metaplasia and
pyometra. We also measured the thickness of
endometrium and myometrium. The parame-
ters of estrogenic effects in the vaginae were
number of epithelial cell layers and their
cornification. In the mammary glands, we
determined the degree of luminal formation
and the presence or absence of secretion.
Quantification of these parameters was per-
formed on three slides per animal; at least
44 slides per group were evaluated.
Statistical analyses. We set the number of
PCNA and PR positive cells per slide in rela-
tion to the total number of alveolar and ter-
minal bud epithelial cells. The percentages of
related values were used to calculate means.
Similarly, we used individual serum hormone
levels and uterine weights to calculate means
and to perform statistical analysis of the data
by analysis of variance followed by Newman-
Keuls post hoc test. Morphologic features
were statistically analyzed with contingency
tables compared with controls. All analyses
were performed with GraphPad PRISM 4
software (GraphPad Software, Inc., San
Diego, CA, USA). Data are presented as
mean ± SEM. 
Results
Animal weights. Table 1 presents body
weights of animals before ovx and on the day
of termination of the experiments. The E2
low and GEN high animals gained signifi-
cantly less weight and the E2 high gained no
weight compared with the control animals.
Serum E2 levels in controls and E2-treated
animals are shown in Figure 1A. Serum E2
concentrations were barely detectable in
control animals, whereas they were in physio-
logic range in the E2 low group and at supra-
physiologic levels in the E2 high group.
Serum luteinizing hormone (LH) levels were
high in control animals, decreased dose-
dependently in the E2 groups, and not
reduced significantly in the GEN groups
(Figure 1B).
Uterus. Both E2 doses and GEN high sig-
nificantly increased uterine weight. With E2
(both doses), uterine weight was around 5-fold
that of controls (Figure 2), and weights were in
the range observed in intact adult female rats
(441.1 ± 18.7 mg in previous experiments
using the same rat strain). GEN high increased
uterine weights only around 2-fold (Figure 2).
Figure 3 shows microscopic preparations of
representative uteri from one animal per treat-
ment group. The morphologic ﬁndings in uteri
of all animals were quantified and are pre-
sented in Table 2. In control uterus we
observed atrophy affecting all structures
(Figure 3A). The endometrium was composed
of cuboidal inactive cells, and the connective
tissue was an unorganized lax syncytium of
round nuclei. No mitotic activity was detected
in epithelial cells. E2 low (Figure 3B) induced
estrogenic features such as large cytoplasms in
endometrial cells, vacuolar degeneration, and
necrosis; we also observed spindle lamina
propria cells intermingled with areas mimick-
ing proestrus of a normal cycle (smaller
nucleus:cytoplasm ratio, less degeneration,
and necrosis). Few pathologic ﬁndings, such
as hypertrophic and hyperplastic glands, were
detected. Mitotic activity was present in
endometrial cells in most animals at various
degrees.
With E2 high (Figure 3C) treatment, all
uterine structures were hypertrophic and
hyperplastic. Although differing in intensity,
endometria were hypertrophic and hyperplastic
Rimoldi et al.
64 VOLUME 115 | SUPPLEMENT 1 | December 2007 • Environmental Health Perspectives
Figure 3. Photomicrographs of representative uteri from one animal per treatment group. (A) Control: atrophic uterus with cuboidal endometrial epithelium and
loose connective tissue composed of round nuclei in an unorganized pattern. (B)E 2 low: the endometrium consists of tall single-layered epithelial cells with abun-
dant mitotic ﬁgures and necrosis (arrowhead); stromal cells of endometrial lamina propria are well organized and spindle shaped. (C)E 2 high: all structures are
hypertrophic and hyperplastic; the endometrial epithelium is multilayered with squamous metaplasia and atypic mitotic figure (arrowhead) surrounded by
anaplastic epithelial nuclei, and keratinized cells are present in the lumen. The square in (C) indicates the area shown at higher magniﬁcation in (F). (D) GEN low:
lamina propria cells adopted an organized pattern (arrowhead), with more condensed nuclei of spindle shape. (E) GEN high: areas of high endometrial prolifera-
tion and unclear inﬂuences on lamina propria cells are present. Arrowheads indicate cells undergoing mitosis. Insets in (A), (B), (D), and (E) show higher magniﬁ-
cations of endometrium. Bar = 80 µm in (A–E) and 20 µm in (F).in 10 of 11 animals (in 1 animal endometrium
could not be analyzed due to severe pyometra)
with squamous metaplasia and anaplastic signs
such as hyperchromatic nuclei with dispersed
chromatin and prominent nucleoli. We
observed various mitotic ﬁgures in endometrial
epithelium and, within these, bizarre mitotic
ﬁgures were apparent. Pyometra also developed
in 5 of 11 animals. Some of these effects in the
E2 high group are shown in Figure 3F (a
bizarre mitotic cell and keratinized cells). The
treatment with GEN low (Figure 3D) induced
negligible effects: Lamina propria cells were
found in some areas in 6 of 12 animals but
epithelial structures in endometrial epithelium
remained unaltered, without hyperplastic/
hypertrophic changes or mitotic activity. In
GEN high animals (Figure 3E), endometrial
cells were stimulated but no pathologic signs
were detected. Endometrial mitotic activity
was found abundantly in 1 of 12, rarely in
2 of 12, and absent in 9 of 12 animals.
Vagina. Figure 4 shows microscopic
preparations of representative vaginae from
one animal per treatment group; the morpho-
logic findings in vaginae of all animals were
quantified and are presented in Table 3.
Atrophic vaginal epithelium was observed in
control animals (Figure 4A); in 12 of 12 rats,
only two to three cell layers were present, and
these were composed of flattened cells with
no corniﬁcation.
The E2 low animals (Figure 4B) displayed
a typical squamous multilayered epithelium.
Approximately 10 cell layers with cornifica-
tion were observed in all 11 samples. Almost
the same changes were seen with E2 high
(Figure 4C) as with E2 low: All 11 animals had
around 10–15 cell layers with corniﬁcation. We
found no clear differences between controls and
GEN animals (Figure 4D). In GEN animals,
epithelium thickness seemed slightly aug-
mented in some areas, the number of cell layers
did not differ from controls (two to three on
average), and no corniﬁcation was found. An
incipient cytoplasmatic vacuolization of epithe-
lial cells was observed in 5 of 12 rats. The treat-
ment with GEN high (Figure 4E) increased
epithelial thickness and also the number of cell
layers (5–10 layers). Corniﬁcation was found
only in 1 of 12 animals, and cytoplasmatic vac-
uolization was clearly present in all samples.
Mammary gland. Figure 5 shows micro-
scopic preparations of representative mammary
glands from one animal per treatment group,
and quantitative data obtained from glands of
all animals are shown in Table 3. In controls
(Figure 5A) all epithelial structures appeared
atrophic. Deep in the fat pad, we observed
scarce clusters of densely packed terminal
structures, many of which did not show lumi-
nal formation. Treatment with E2 low
(Figure 5B) induced formation of small
lumina, but no secretory material was detected.
Terminal epithelial structures were abundant
after treatment with E2 high (Figure 5C).
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Figure 4. Photomicrographs of representative vaginal sections from one animal per treatment group. (A) Control: atrophic vaginal epithelium is composed of a few
layers of ﬂattened cells. (B)E 2 low: vaginal epithelium is hypertrophic and hyperplastic, with corniﬁcation in the upper layers. (C)E 2 high: stronger hypertrophy
and hyperplasia of epithelium are present; compared with E2 low, there are more cell layers and a higher degree of corniﬁcation. (D) GEN low: atrophic vaginal
epithelium and the thickness and number of layers resemble that of control animals, but some areas have an incipient cytoplasmatic vacuolization (arrowheads).
(E) GEN high: vaginal epithelium is increased (5–10 cells per layer on average), and large cytoplasmatic vacuoles are present in the upper layers. Bar = 80 µm.
Table 2. Summary of physiologic and pathologic ﬁndings in uteri of ovx rats after treatment with E2 or GEN.
Physiologic Pharmacologic E2-induced ﬁndings by degree of severity
Uterine Spindle-shaped Endometrial epithelium Hyperplastic/ Squamous Cystic
Treatment weight (mg) lamina propria cells with mitosis hypertrophic glands metaplasia glands Pyometra
Control 91.6 0/12 0/12 0/12 0/12 0/12 0/12
E2 low 478.4* 11/11 11/11 6/11 0/12 0/12 0/12
E2 high 548.5* 10/10 10/11 10/10 9/11 4/10 5/11
GEN low 87.92 6/12 0/12 0/12 0/12 0/12 0/12
GEN high 196.8* 12/12 12/12 0/12 0/12 0/12 0/12
*p < 0.05 vs. control.Luminal formation was present in all animals,
and secretion was seen in 9 of 11 animals. Both
GEN treatments (Figure 5D, E) were only
slightly different from controls: No secretion
was induced, and incipient luminal formation
was present in one-half of the animals of both
groups. An overview of all collected data,
including their significance, is presented in
Table 4.
PCNA and PR immunostaining. Figure 6A
shows representative PCNA-immunostained
section of mammary gland from a control ani-
mal, and Figure 6B shows a tissue section from
an E2 high animal. In mammary gland samples
immunostained for PCNA (Figure 6C) or PR
(Figure 6D), the number of PCNA- or PR-
expressing cells was counted and expressed as a
percentage of the total number of cells. E2
stimulated expression of PCNA dose depen-
dently, and GEN also stimulated expression of
this proliferation marker (Figure 6C).
PR-expressing nuclei were found only in
mammary gland cells of animals treated with
E2 and GEN (both doses of each; Figure 6D).
E2 low was more effective in increasing the
number of PR-expressing cells than was
E2 high.
Discussion
In the present study we compared the effects of
two doses of genistein with those of two doses
of E2 in ovx rats. We chose these doses on the
basis of published data (Diel et al. 2004;
Tinwell and Ashby 2004) and compared them
with those used in recently published studies
(Hertrampf et al. 2006; Michael McClain et al.
2006). The route and the duration of applica-
tion were chosen because little information is
available about the effects of subchronically
and orally administered GEN in the uterus and
mammary gland tissue of ovx rats (Hertrampf
et al. 2006; Michael McClain et al. 2006).
Michael McClain et al. (2006) reported that
GEN at 500 mg/kg/day (higher than doses
used in the present study) had no estrogenic
effect in the uterus or the mammary gland; the
animals in those experiments however were not
ovx. Because we sought an animal model that
might be comparable to postmenopausal
women, we used ovx rats, which are in line
with the Organisation for Economic Co-opera-
tion and Development recommendation to test
for estrogenicity either in immature or ovx rats
(Kanno et al. 2001). Hertrampf et al. (2006)
used ovx rats and GEN doses similar to those
used in the present study, but studied the
effects after only 3 days of oral application. In
agreement with our data, they observed estro-
genic effects of GEN in the mammary gland
(PR expression was increased) and a mild
uterotrophic effect of GEN.
GEN is known to bind to both estrogen
receptors, with a slight preference for ER-β.
Data from ER-α–knock-out mice suggest that
the ER-α is the receptor that mediates the typi-
cal effects of E2 in the uterus, vagina, and
Rimoldi et al.
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Figure 5. Photomicrographs of representative mammary gland sections from one animal per treatment group. (A) Control: a small cluster of densely packed epithe-
lial cells without luminal formation are present in the deep subcutaneous fat pad. (B)E 2 low: a few terminal structures with small lumina but without secretory
material. (C)E 2 high: well-formed acinar and luminal structures with secretory material in the lumina. In GEN low (D) and GEN high (E), there is almost no cellular or
acinar difference from control. Bars = 80 µm.
Table 3. Effects of treatment with E2 or GEN on morphologic features of vagina in ovx rats.
Cell layers Vacuolization 
Group 1–5 > 5 to < 10 10 > 10 Keratinization Incipient Clear
Control 12/12 0/12 0/12 0/12 0/12 0/12 0/12
E2 low 0/12 0/12 11/11 0/12 11/11* 0/12 0/12
E2 high 0/12 0/12 0/12 11/11 11/11* 0/12 0/12
GEN low 12/12 0/12 0/12 0/12 0/12 5/12 0/12
GEN high 0/12 0/12 5/12 0/12 1/12 0/12 12/12*
*p < 0.05 compared with control.mammary gland (Couse and Korach 1999;
Hewitt and Korach 2003). Most studies have
addressed effects of E2 and GEN in these
organs after a relatively short duration of appli-
cation, and reports about longer-lasting effects
particularly in the mammary gland are scarce.
In the present study, administration of the two
doses of E2 added to the daily food for
3 months resulted in high physiologic serum
concentrations of E2 low and in supra-
physiologic concentrations of E2 high. Serum
LH concentrations were suppressed under
both doses, which is typical for E2, whereas
neither GEN dose affected LH serum values.
Using LH serum levels as a marker of estro-
genic effect in the hypothalamus—where the
gonadotropin-releasing hormone pulse genera-
tor resides—GEN seems to be ineffective in
reducing the activity of this brain structure.
This may also explain the clinical ﬁnding that
GEN did not substantially alleviate hot ﬂashes
(Geller and Studee 2005). Indeed, in women
suffering from climacteric complaints, few
placebo-controlled trials yielded significant
effects of isoflavones. The placebo educed
climacteric complaints by 30–50%, which was
similar to the effectiveness of isoflavones
(Geller and Studee 2005; Krebs et al. 2004;
Phipps et al. 2002). Upon gross morphologic
analyses, ovx animals had very low uterine
weights; in animals treated with either E2 dose,
uterine weight was increased to the range of
that of intact animals. GEN high animals had
increased uterine weight, whereas GEN low
animals did not.
Histologic analysis of effects of both E2
doses revealed well-known morphologic
changes in uterus (Cummings and Yochim
1984; Fazleabas and Strakova 2002). Under
physiologic conditions of proestrus and
estrus, the nuclei of lamina propria stromal
cells depict a spindle shape and an organized
cell pattern (Cummings and Yochim 1984;
Fazleabas and Strakova 2002; Yuan 2002).
We observed this pattern in one-half of the
GEN low animals, in all GEN high animals,
and in both E2 groups; in the controls, cells
remained round and densely packed.
Endometrial epithelial cells were also affected
by E2 and GEN. During the course of an
estrous cycle, E2 induces mitotic replication
of cells and induces epithelial cells to adopt a
tall cylindrical shape. Hence, in E2-treated
animals, the epithelial cells depict such cylin-
drical shape with a high cytoplasmic:nuclear
ratio. We observed changes like these mainly
in the E2 low and GEN high animals. Under
supraphysiologic doses of E2, we noted some
pathologic features. Cells from epithelial
glands were hypertrophic and hyperplastic,
and the endometrial epithelium was multi-
layered and often developed squamous meta-
plasia. We did not observe such pathologic
features in the GEN-treated animals. E2 also
widens the lumen of the uterine cervix, which
under chronic conditions allows bacterial
ascension that may result in development of
pyometras. Consequently, we found pyome-
tras in some animals treated with E2 high.
The morphologic changes induced by E2 or
GEN in uterus are similar, differing only in
degree. These results suggest that GEN has
similar although weaker effects than E2 in the
rat uterus.
Vaginal epithelium also subject to estro-
genic action in that E2 causes proliferation and
corniﬁcation. In the present study, we observed
increased vaginal epithelial height, number of
layers, and cornification in all samples from
both E2 groups, with a stronger effect in the E2
high group. GEN low increased epithelial
height only slightly; GEN high dose, however,
increased numbers of layers comparable to
E2 high. A different feature, namely, cytoplas-
matic vacuolization, was detected in the GEN
animals at incipient degrees in the low-dose
animals and clearly in the high-dose animals.
Cytoplasmatic vacuolization was not observed
in any of the E2-treated animals. Hence, the
morphologic changes induced by GEN in
vaginal epithelium are not identical with those
exerted by E2, suggesting that the mechanisms
by which this phytoestrogen and its gut
metabolites (e.g., equol) affect vaginal epithe-
lium are different from those mediating the
effects of E2.
Mammary gland tissue was scarce in the
ovx control rats, and the few detectable termi-
nal structures were collapsed. E2 low induced
luminar formation but no secretion, whereas in
the mammary gland of E2 high animals, ample
tissue and signs of secretion were observed.
GEN did not have marked effects on mam-
mary gland morphology; half of the animals in
each GEN dose group had an incipient lumi-
nal formation. PCNA is a nuclear protein that
is expressed in proliferating cells during the
S phase of the cell cycle and is a useful tool in
mammary cancer prognosis research (Kurki
et al. 1986; Schimmelpenning et al. 1993). It
can be visualized by immunohistochemistry;
this allows the estimation of the percentage of
Effects of genistein in reproductive organs
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Figure 6. Results of immunostaining for PCNA (A,C) and PR (B,D) in mammary gland. (A) Photomicrograph
showing PCNA immunostaining in control tissue. (B) Photomicrograph showing PR immunostaining in
E2 high mammary gland. Percentage of PCNA-positive (C) and PR-expressing (D) epithelial cells in mam-
mary terminal structures. Immunostained PCNA cells were regularly seen in all animals (C). PR-expressing
cells were seen in both in E2 groups and in the GEN high group (D); note the reduced number of PR-
expressing cells in E2 high versus E2 low mammary glands. Bars = 20 µm.
*p < 0.05 compared with control; **p < 0.05 compared with E2 low.
Table 4. Effects of treatment with E2 or GEN on morphologic features of mammary glands in ovx rats.
Luminal formation
Group Absent Incipient Clear Secretion
Control 6/12 6/12 0/12 0/12
E2 low 0/12 0/12 11/11* 0/11
E2 high 0/12 0/12 11/11* 9/11*
GEN low 6/12 6/12 0/12 0/12
GEN high 6/12 6/12 0/12 0/12
*p < 0.05 compared with control.Rimoldi et al.
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proliferating cells in relation to the total num-
ber of cells. In deep terminal mammary struc-
tures, epithelial proliferation was increased by
both E2 doses; PCNA analysis also indicates
that GEN has a stimulatory effect on mam-
mary gland epithelial cells. Stimulation of
mammary cell proliferation is an increased risk
factor for the development of cancer
(Gadducci et al. 2005).
Stimulation of PR in mammary epithelial
cells is another typical effect of E2, which we
observed in the animals treated with both E2
doses and GEN high; however, we counted
significantly fewer PR-expressing cells in the
E2 high tissues compared with the E2 low tis-
sues. The reason the E2 high did not stimulate
PR receptor as profoundly as did E2 low
remains obscure, particularly in view of the
profound stimulation of mammary duct tissue
with luminal formation and secretory activity
by the E2 high.
In summary, we found that GEN had
similar but milder effects in the uterus than
E2, without showing any selective ER modula-
tor properties. Also, mammary gland prolifera-
tion was increased under both E2 and GEN.
In the hypothalamus and vagina GEN exerted
different effects compared with E2. LH release
was unaltered, suggesting that GEN did not
exert the estrogenic negative feed back on
GnRH in the rat hypothalamus. The clearest
finding that GEN does not act exactly the
same as E2 was found in the vaginal epithe-
lium, where GEN high induced a different
feature: cytoplasmatic vacuolization.
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